Cytokinetics, Incorporated
CYTK
Positions held
Your positionsCYTK isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Cytokinetics is positioned in the biotechnology sector, focusing on innovative treatments that address unmet medical needs, which can drive future growth.
- In the latest quarter, Cytokinetics reported a revenue increase of 48% compared to the prior quarter, reaching $29 million.
- The company maintains a strong current ratio of 6.661, indicating good short-term financial health.
- Cytokinetics faces significant financial challenges, with a negative profit margin and ongoing operating losses that raise concerns about sustainability.
- The operating margin for the latest quarter was -626%, reflecting ongoing operational inefficiencies.
- The company's overall score indicates a 'Strong Sell' signal, with a score of -16.00 based on various bearish indicators.
Fundamentals
| Market cap | $8.62B | Enterprise value | $8.88B | Trailing P/E | — | Forward P/E | -13.95 |
| PEG | — | Price / book | -49.61 | Beta | 0.41 | Dividend yield | 0.00% |
| Revenue growth | -57.1% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -6.3% |
| Profit margin | 0.0% | ROE | — | ROA | -28.1% | Debt / equity | — |
| Current ratio | 6.66 | Free cash flow | -$397.41M | Analyst recommendation | strong_buy | Mean target | $109.95 |
| 52w high | $88.31 | 52w low | $54.30 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $28.6M | $19.4M | $17.8M | $1.9M | $66.8M | — |
| Op margin | -626.0% | -948.7% | -1004.6% | -8613.4% | -167.0% | — |
| Net income | -$199M | -$206M | -$183M | -$306M | -$134M | — |
| Gross margin | 80.5% | 86.8% | -488.0% | -5025.7% | 96.4% | — |
| Gross profit | $23.0M | $16.8M | -$86.6M | -$97.3M | $64.4M | — |
| Operating income | -$179M | -$184M | -$178M | -$167M | -$112M | — |
- Revenue +48% vs prior quarter ($29M vs $19M).
- Gross margin 80.5% (was 86.8% prior quarter).
- Operating margin expanded to -626%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $88.0M | $18.5M | $7.5M | $94.6M |
| Op margin | -695.4% | -2902.7% | -6589.7% | -342.8% |
| Net income | -$785M | -$590M | -$526M | -$389M |
| Gross margin | -372.5% | -1737.2% | -4284.1% | -154.6% |
| Gross profit | -$328M | -$321M | -$323M | -$146M |
| Operating income | -$612M | -$536M | -$496M | -$324M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · RBC Lifts Price Target on Cytokinetics to $113 From $112, Keeps Outperform Rating
2026-10-02 · Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
2026-10-02 · Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
2026-09-30 · Cytokinetics Starts Real-World Study of Myqorzo in Obstructive Hypertrophic Cardiomyopathy
2026-09-28 · Cytokinetics Insider Sold Shares Worth $490,950, According to a Recent SEC Filing
2026-09-25 · Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
2026-09-23 · Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?
2026-09-17 · Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-14 · Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
2026-09-10 · Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
2026-09-08 · Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?
Price (daily)
Full chart · RSI · MACD · patterns